The managed-care industry is navigating a more challenging growth environment as insurers balance rising medical costs, changing Medicare Advantage dynamics and the need for disciplined pricing. These factors are putting greater emphasis on profitability, membership quality and the ability to manage care efficiently while sustaining long-term growth. Against this backdrop, UnitedHealth Group Incorporated UNH and Elevance Health, Inc. ELV operate across overlapping health insurance markets, making them closely comparable peers within the managed-care sector.
UnitedHealth combines its insurance operations with a broad health-services platform, while Elevance is leveraging its insurance business alongside Carelon to expand its healthcare services capabilities. Their differing business mixes and approaches to Medicare Advantage and care management provide a useful basis for comparing fundamentals, growth prospects and strategic direction.
Let’s dive deep and closely compare the fundamentals of the two stocks to determine which one is a better investment now.
The Case for UNH
UnitedHealth, with a current market cap of $357.8 billion, has several avenues to support growth as its core insurance business, UnitedHealthcare, improves and Optum gains momentum. UnitedHealthcare’s Medicare business is benefiting from tighter benefit design, care management and network curation, with a greater emphasis on profitability and sustainable returns rather than pursuing membership growth at any cost. The company is focusing its Medicare portfolio on plans that can deliver appropriate returns while maintaining value for members. UNH expects Medicare Advantage margins to finish 2026 above 3%.
OptumHealth provides another key growth engine, with the business focused on expanding its integrated value-based care model across primary and specialty care, ambulatory surgery and home health. Its care-transition initiatives have reduced hospitalizations by roughly 10% in its Western and Southern regions. OptumHealth also reaches nearly 90% of U.S. counties and conducts around 2.5 million rural home visits annually, with plans to expand these programs across its footprint by the end of 2026.
UNH is also investing heavily in technology and AI to simplify health care and improve operating efficiency. The company plans to eliminate 30% of prior-authorization volume by the end of 2026, along with nearly two-thirds of prior-authorization requirements for pediatric care. At OptumHealth, AI-based ambient listening is already available to 70% of employed providers and is expected to exceed 90% by year-end, while further investments in clinical workflows, automation and network performance are planned. Optum Rx and Optum Insight add further opportunities through transparency, AI-enabled services and value-based solutions.
In the second quarter of 2026, UNH’s consolidated revenues rose 0.4% year over year. Its consolidated medical care ratio improved to 86.7% in the quarter from 89.4% a year ago. Meanwhile, the company’s adjusted EPS rose 56.4% year over year in the second quarter of 2026 and raised its 2026 adjusted EPS outlook to $19.50-$20. UNH beat earnings estimates in each of the past four quarters, with an average surprise of 12.1%.
Financially, UNH is in a solid position. It ended the second quarter of 2026 with $31.5 billion in cash and short-term investments, sufficient to cover its short-term borrowings and current maturities of long-term debt, which stands at $3.8 billion. Its long-term debt-to-capital of 40.4% is below ELV’s 40.5%. In the first half of 2026, it paid dividends worth $4.1 billion.
The Case for ELV
Elevance, with a current market cap of $87.3 billion, is building its growth outlook around a broader recovery across Medicare Advantage, individual ACA, commercial benefits and Carelon. Medicare Advantage performance has improved following tighter plan design and a more focused product mix, supporting a path to at least a 2% operating margin in 2026. In the second quarter of 2026, its health benefits segment’s revenues grew 2.7% year over year, along with 6.3% growth in the total Carelon unit.
Carelon is emerging as a more meaningful contributor to ELV's longer-term growth. Its behavioral health programs have generated average cost savings of about 10% by identifying members earlier and coordinating care more effectively. CareBridge is also being expanded into new markets and can generate medical savings in the mid-teens for the members it serves. Further expansion into complex areas such as behavioral health and oncology could increase the contribution from Carelon's value-based model over time.
ELV is investing heavily in technology and data-driven capabilities. Investments in Sydney Health, concierge care and proactive member engagement are designed to make care navigation more personalized, while HealthOS is helping providers review care plans earlier, reduce delays and limit administrative friction. It is also accelerating investments in medical cost management, provider connectivity and AI-enabled capabilities, with HealthOS tools targeting fewer documentation requests, better prior authorization and greater use of real-time processes.
The company is also positioning its commercial and pharmacy businesses for longer-term expansion. Its integrated medical and pharmacy offering is seeing demand, particularly for patient advocacy, behavioral health and digital engagement services, while CarelonRx is seeing early progress in the 2027 selling season. ELV has raised its 2026 adjusted EPS guidance to at least $27 and is targeting at least 12% adjusted EPS growth in 2027, supported by health benefits, Carelon growth, operating efficiency and disciplined capital deployment. It beat earnings estimates in each of the past four quarters, with an average surprise of 16.6%.
ELV exited the second quarter of 2026 with a solid liquidity position, holding $10.2 billion in cash and cash equivalents. The company also demonstrates relatively stronger capital efficiency, with a return on invested capital of 7.8%, notably higher than UnitedHealth at 6.2%. However, its dividend yield of 1.7% is lower than that of UNH’s 2.3%.
How Do the Estimates Compare for UNH & ELV?
The Zacks Consensus Estimate favors UNH at this stage. The consensus estimate for UNH’s 2026 earnings indicates a 21.2% increase from a year ago. Meanwhile, the consensus estimate for revenues suggests a 0.2% decline. On the other hand, the consensus estimate for ELV’s 2026 earnings indicates a 10.6% fall from a year ago, while the same for revenues suggests a 1.2% decline.
Valuation: UNH vs. ELV
Coming to the valuation story, it seems that investors are willing to pay a premium for UnitedHealth compared to Elevance. This is reflected in UNH’s forward 12-month price/earnings (P/E) of 18.47X compared with ELV’s 14.07X.
Image Source: Zacks Investment Research
Price Performance Comparison
Over the past year, UNH shares have outperformed ELV and the S&P 500.
Price Performance – UNH, ELV & S&P 500
Image Source: Zacks Investment Research
Price Target
UNH currently trades below its average analyst price target of $481.52, implying an attractive 23.4% potential upside from current levels. Meanwhile, ELV also trades below its average analyst price target of $447.85, implying an 11.8% potential upside from current levels.
Conclusion
Overall, Elevance offers attractive long-term potential through Carelon, disciplined Medicare Advantage management and technology investments, but its earnings are expected to decline in 2026. Meanwhile, UnitedHealth’s improving Medicare profitability, Optum’s value-based care opportunities, strong earnings growth outlook and greater expected upside provide a more compelling combination of growth and recovery potential. UNH also has a stronger balance sheet and higher dividend yield than ELV.
With stronger earnings prospects and a more favorable risk-reward profile, UNH appears better positioned to deliver stronger returns, making it the more compelling choice between the two stocks. Currently, UnitedHealth sports a Zacks Rank #1 (Strong Buy), while Elevance has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report
Elevance Health, Inc. (ELV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
